In 2003, Johnson et al. reported that the median percentage of CD4+/CD25+ T lymphocytes was greater after 2 and 6 weeks of anti-TB treatment in subjects receiving rhulL-2 than in those receiving placebo [29]. The gene discussed is CD4; the disease is tuberculosis.